[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100652550":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":26,"responsibleParty":41,"collaborators":10,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":47,"sex":52,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":58,"studyType":59,"phases":10,"briefSummary":60,"conditions":61,"keywords":69,"overallStatus":80,"whyStopped":10,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Helse Stavanger HF","OTHER_GOV",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"STELIR Cohort",null,"Participants enrolled in the STELIR (STEatotic LIver Risk in Rogaland) cohort will be followed longitudinally as part of an observational research biobank. The cohort includes adults at increased risk of steatotic liver disease based on predefined metabolic and lifestyle risk factors.\n\nNo intervention is assigned. Participants undergo standardized clinical assessments and biological sample collection as part of routine study procedures.",[13],"Other: Routine study procedure",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"OTHER","Routine study procedure","Routine study procedures include: Informed consent, medical history and clinical examination, structured questionnaires (lifestyle, alcohol use, metabolic risk factors), liver elastography, blood sample collection for clinical analyses and biobanking.\n\nAssessments are conducted at baseline, after 2 years, after 5 years, and subsequently every 5 years.",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"Torgeir Gilje Lid, Professor","CONTACT","+47 51513325","sb_hst_forskpost@ihelse.net",[27],{"facility":28,"status":10,"city":29,"state":10,"zip":10,"country":30,"countryCode":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"Stavanger University Hospital","Stavanger","Norway","NO",{"type":33,"coordinates":34},"Point",[35,36],5.73332,58.97005,{"lat":36,"lon":35},[39],{"name":40,"role":23,"phone":24,"phoneExt":10,"email":25},"Forskningsposten, Stavanger University Hospital",{"type":42,"investigatorFullName":43,"investigatorTitle":44,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Torgeir Gilje Lid","Research leader and professor of general practice","100652550","detecting-liver-fibrosis-in-patients-at-risk-100652550",false,"NCT07775638","Detecting Liver Fibrosis in Patients At-risk","STELIR","Inclusion Criteria:\n\n* Age 40 to 70 years at the time of inclusion\n* At least one of the following risk factors: Overweight or obesity, type 2 diabetes mellitus, risky or harmful alcohol consumption\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Inability to give informed consent\n* Individuals outside the defined age range\n* Other conditions precluding participation based on investigator assessment","ALL","40 Years","70 Years",{"count":56,"type":57},1200,"ESTIMATED","20 Years","OBSERVATIONAL","The project will establish a research cohort (called STELIR; STEatotisk Liver-risk In Rogaland) based on a biobank with an associated health register. The purpose is to collect, store and analyze biological material and clinical data from people at risk of steatotic liver disease (fatty liver disease). The research cohort will consist of individuals who agree to participate and will be followed over many years with planned examinations\u002Ftests at baseline, after 2 years, after 5 years and every 5 years thereafter. The STELIR cohort consists of individuals between 40 and 70 years of age who have one or more of the following risk factors: Obesity, type 2 diabetes or hazardous or harmful alcohol consumption.\n\nThe biological material and clinical data collected will be stored and used for research on liver-related disease risk, diagnostics and treatment.",[62,63,64,65,66,67,68],"Fatty Liver","NAFLD - Non-Alcoholic Fatty Liver Disease","Nash","MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)","Biomarker in Early Diagnosis","Liver Disease (Alcoholic or Not)","Cirrhoses, Liver",[70,71,72,73,74,75,76,77,78,79],"Primary care","General practice","early detection","risk stratification","case finding","Clinical prediction tools","Biomarkers","Non-invasive tests","Liver enzymes","Fibrosis assessment","NOT_YET_RECRUITING","2026-08-19",{"date":83,"type":84},"2026-08-20","ACTUAL",{"date":86,"type":57},"2026-08",{"date":88,"type":57},"2070-12-31",{"name":5,"class":6},1]